Thread by @MonicaGandhi9

U.S. trial of AztraZeneca results out. 32,449 adult participants, 2 doses, 4 wks apart. 5 cases of severe COVID-19 illness and all in placebo arm so protects against this (from WaPo article). 141 cases total, 79% effective, 80% in those >65; no clots
apnews.com/article/us-dat…

Think great to have 4th option. But agree with this article is U.S. isn't going to use the doses, then please donate them
nytimes.com/2021/03/17/opi…

Here is actual press release from U. of Oxford on the new trial- conducted in U.S., Chile, Peru. Must have given more details to reporters to get the above, but the page also includes all the previous AZ data and the real-world data so nice summary overall
ox.ac.uk/news/2021-03-2…

And here is Washington Post article with 5 severe outcomes from COVID-19 in placebo arm; 0 in vaccine arm
washingtonpost.com/world/europe/a…

Here is press release from NIH on AZ. 32,449 participants enrolled across 88 sites in the U.S, Chile and Peru. One participant received a placebo for every two participants who received AZD1222, resulting in approximately 20,000 people receiving vaccine.
nih.gov/news-events/ne…

Two doses of 5 x10^10 viral particles four weeks apart.
Vax 78.9% in preventing symptomatic COVID-191 00% ,efficacy in preventing severe or critical disease and hospitalization (only 5 though). In >=65 years, vaccine efficacy against symptomatic COVID-19 was 79.9%.

Review of thrombotic events (blood clots) & cerebral venous sinus thrombosis (CVST) found no increased risk in vaccinated participants. Diversity: 79% white, 22% Hispanic, 8% Black or African American, 4% Native American, 60% had comorbidities predisposing to severe illness